Evidence map›Paper›PMID 16320102›Full record

ArticleJournal of pharmacokinetics and pharmacodynamics2005

Collapsing mechanistic models: an application to dose selection for proof of concept of a selective irreversible antagonist.

Matthew M Hutmacher, Debu Mukherjee, Kenneth G Kowalski, David C Jordan

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Journal of pharmacokinetics and pharmacodynamics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Fractional dynamics pharmacokinetics-pharmacodynamic models.Journal of pharmacokinetics and pharmacodynamics · 2010
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Matthew M HutmacherPfizer Corporation Pharmacometrics, 2800 Plymouth Road, Ann Arbor, MI 48015, USA. matt.hutmacher@pfizer.com
Debu Mukherjee
Kenneth G Kowalski
David C Jordan
Pfizer (United States) · USAbbott (United Kingdom) · GBBiostatistical Consulting (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

When data fail to support fully mechanistic models, alternative modeling strategies must be pursued. Simpler, more empirical models or the fixing of various rate constants are necessary to avoid over-parameterization. Fitting empirical models can dilute information, limit interpretation, and cloud inference. Fixing rate constants requires external, relevant, and reliable information on the mechanism and can introduce subjectivity as well as complicate determining the validity of model extrapolation. Furthermore, both these methods ignore the possibility that failure of the data to support the mechanistic model could contain information about the pharmacodynamic process. If the pathway has processes with "fast" dynamics, these steps could collapse yielding parametrically simpler classes of models. The collapsed models would retain the mechanistic interpretation of the full model, which is crucial for performing substantive inference, while reducing the number of parameters to be estimated. These concepts are illustrated through their manifestations on the dose-effect relationship and ensuing dose selection for a proof of concept study. Specifically, a mechanistic model for a selective irreversible antagonist was posited and candidate classes of models were derived utilizing "fast dynamics" assumptions. Model assessment determined the rate-limiting step facilitating pertinent inference with respect to the mechanism. For comparison, inference using a more empirical modeling strategy is also presented. A general solution for the collapse of the typical PK-PD model differential equations is provided in Appendix A.

Indexed as

Models, BiologicalAdministration, OralClinical Trials as TopicDose-Response Relationship, DrugEnzyme InhibitorsHumansEnzyme Inhibitors

Identifiers

PMID16320102
OpenAlexW1964181234

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.